CARNOT THERAPEUTICS Trademark

Trademark Overview

On Tuesday, December 4, 2018, a trademark application was filed for CARNOT THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the CARNOT THERAPEUTICS trademark a serial number of 88216430. The federal status of this trademark filing is REGISTERED as of Tuesday, January 7, 2020. This trademark is owned by Carnot, LLC. The CARNOT THERAPEUTICS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Drug discovery and development services
carnot therapeutics

General Information

Serial Number88216430
Word MarkCARNOT THERAPEUTICS
Filing DateTuesday, December 4, 2018
Status700 - REGISTERED
Status DateTuesday, January 7, 2020
Registration Number5953073
Registration DateTuesday, January 7, 2020
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 22, 2019

Trademark Statements

Disclaimer with Predetermined Text"THERAPEUTICS"
Goods and ServicesDrug discovery and development services

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, December 21, 2018
Primary Code042
First Use Anywhere DateTuesday, March 1, 2016
First Use In Commerce DateTuesday, March 1, 2016

Trademark Owner History

Party NameCARNOT PHARMA, LLC
Party Type30 - Original Registrant
Legal Entity Type16 - Limited Liability Company
AddressBOSTON, MA 02116
Party NameCARNOT PHARMA, LLC
Party Type21 - New Owner After Publication
Legal Entity Type16 - Limited Liability Company
AddressBOSTON, MA 02116
Party NameCarnot, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressBoston, MA 02166
Party NameCarnot, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressBoston, MA 02166

Trademark Events

Event DateEvent Description
Tuesday, March 2, 2021APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, March 2, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, March 2, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, March 2, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, March 2, 2021TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, July 23, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, July 23, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, July 23, 2020TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Thursday, July 23, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, July 23, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, July 23, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, January 7, 2020REGISTERED-PRINCIPAL REGISTER
Wednesday, October 23, 2019AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Tuesday, October 22, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 22, 2019PUBLISHED FOR OPPOSITION
Wednesday, October 2, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, September 18, 2019ASSIGNED TO LIE
Monday, September 16, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, August 28, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, August 27, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, August 27, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, March 7, 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, March 7, 2019NON-FINAL ACTION E-MAILED
Thursday, March 7, 2019NON-FINAL ACTION WRITTEN
Thursday, March 7, 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, March 7, 2019NON-FINAL ACTION E-MAILED
Thursday, March 7, 2019NON-FINAL ACTION WRITTEN
Tuesday, March 5, 2019ASSIGNED TO EXAMINER
Friday, December 21, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, December 7, 2018NEW APPLICATION ENTERED IN TRAM

Related Keywords

therapeutics carnot services development discovery drug